Literature DB >> 11015622

Role of platelet-activating factor in cardiovascular pathophysiology.

G Montrucchio1, G Alloatti, G Camussi.   

Abstract

Platelet-activating factor (PAF) is a phospholipid mediator that belongs to a family of biologically active, structurally related alkyl phosphoglycerides. PAF acts via a specific receptor that is coupled with a G protein, which activates a phosphatidylinositol-specific phospholipase C. In this review we focus on the aspects that are more relevant for the cell biology of the cardiovascular system. The in vitro studies provided evidence for a role of PAF both as intercellular and intracellular messenger involved in cell-to-cell communication. In the cardiovascular system, PAF may have a role in embryogenesis because it stimulates endothelial cell migration and angiogenesis and may affect cardiac function because it exhibits mechanical and electrophysiological actions on cardiomyocytes. Moreover, PAF may contribute to modulation of blood pressure mainly by affecting the renal vascular circulation. In pathological conditions, PAF has been involved in the hypotension and cardiac dysfunctions occurring in various cardiovascular stress situations such as cardiac anaphylaxis and hemorrhagic, traumatic, and septic shock syndromes. In addition, experimental studies indicate that PAF has a critical role in the development of myocardial ischemia-reperfusion injury. Indeed, PAF cooperates in the recruitment of leukocytes in inflamed tissue by promoting adhesion to the endothelium and extravascular transmigration of leukocytes. The finding that human heart can produce PAF, expresses PAF receptor, and is sensitive to the negative inotropic action of PAF suggests that this mediator may have a role also in human cardiovascular pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015622     DOI: 10.1152/physrev.2000.80.4.1669

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  87 in total

1.  Role of the platelet-activating factor (PAF) receptor during pulmonary infection with gram negative bacteria.

Authors:  A C Soares; V S Pinho; D G Souza; T Shimizu; S Ishii; J R Nicoli; M M Teixeira
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

2.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor.

Authors:  Kimberly D Dyer; Caroline M Percopo; Zhihui Xie; Zhao Yang; John Dongil Kim; Francis Davoine; Paige Lacy; Kirk M Druey; Redwan Moqbel; Helene F Rosenberg
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

4.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

5.  Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.

Authors:  John Doukas; Wolfgang Wrasidlo; Glenn Noronha; Elena Dneprovskaia; Richard Fine; Sara Weis; John Hood; Anthony Demaria; Richard Soll; David Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

6.  Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.

Authors:  Yong-Ping Yang; Xue-Mei Ma; Chun-Ping Wang; Jun Han; Yin-Ying Lu; Yi Xiang; Shu-Hui Su; Yong-Yi Feng
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 7.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

8.  Ability to induce atrial fibrillation in the peri-operative period is associated with phosphorylation-dependent inhibition of TWIK protein-related acid-sensitive potassium channel 1 (TASK-1).

Authors:  Erin Harleton; Alessandra Besana; George M Comas; Peter Danilo; Tove S Rosen; Michael Argenziano; Michael R Rosen; Richard B Robinson; Steven J Feinmark
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

9.  Gq-dependent signaling upregulates COX2 in glomerular podocytes.

Authors:  Liming Wang; Patrick J Flannery; Paul B Rosenberg; Timothy A Fields; Robert F Spurney
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

10.  Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor.

Authors:  Zhili Xu; Jeffrey S Smith; Jie Tian; Andrew P Byrnes
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.